Nigeria US Health Compact and The Duty To Inform

Public confidence in international agreements depends not only on the deal negotiated, but on government’s willingness to disclose, explain and defend it.

Nigeria may have negotiated a defensible health agreement with the United States. But citizens should not have to reconstruct its implications from a foreign president’s interview and documents scattered across external websites.

The controversy exposes a governance failure that deserves attention regardless of the eventual verdict on the agreement: inadequate public explanation of a consequential national decision.

“Public scrutiny requires access to the terms of agreements made in citizens’ names.”

President John Dramani Mahama’s account of Ghana’s rejection of a proposed US health compact has reopened questions Nigeria should already have answered.

Speaking at the Council on Foreign Relations on 25 September 2026, he described concerns about pathogen information, medical records, domestic financing and restrictions on inspecting incoming medical products.

These were his account of Ghana’s proposed terms. They do not establish what Nigeria accepted.

That distinction matters. There is insufficient evidence to conclude that Nigeria signed up to the exact conditions Ghana rejected.

A common American policy framework does not establish identical agreements. Responsible public debate must resist converting similarity into proof.

I hold no brief for the Nigerian government. Its public explanation has not furnished a sufficiently complete basis for an informed defence of the entire arrangement. Equally, an information gap cannot establish every allegation made against it.

We should demand evidence from government while holding our own conclusions to the same standard.

What the available documents establish

It would be inaccurate to say government has communicated nothing.

The Federal Ministry of Health announced the agreement in December 2025, described its health objectives and presented nearly $2 billion in anticipated US grants alongside nearly $3 billion in Nigerian domestic financing.

It framed the partnership as a transition towards self-reliance. That is an explanation of purpose, but it does not settle questions about the conditions.

The published Nigerian MoU contains safeguards. It envisages case-by-case committee approval for specimen sharing, regulated audit access, and a data arrangement respecting relevant laws, ownership and hosting requirements.

It describes itself as non-binding. I found no blanket prohibition on NAFDAC inspecting American medical products in that main text.

Its reference to regulatory reliance should not automatically be interpreted as surrender of inspection powers.

However, the separate signed specimen-sharing agreement deserves scrutiny.

It permits onward sharing with qualifying US entities, with notification to Nigeria; access to resulting medical countermeasures is qualified by funding availability and applicable law. Termination does not end US use of materials already shared.

The agreement entered into force in January 2026 and has a five-year term renewable by mutual agreement.

These are material provisions that citizens should have had explained alongside the announcement of benefits.

Public Citizen’s document collection provides the main Nigerian MoU and specimen agreement, but no Nigerian data-sharing text.

Without that instrument, or authoritative clarification of its status, the public cannot fully assess the data-access bargain.

Information management is a governing duty

Good information management begins before a controversy. It requires accurate records, clear responsibility for decisions, accessible disclosure and an explanation that allows citizens to distinguish an obligation from an aspiration. It also requires correction when public understanding is wrong. This is more demanding than public relations. A press release may announce an achievement.

Governance must explain the trade-offs behind it, identify who protects the public interest and show how those protections can be enforced.

When public health information and biological resources are involved, citizens have reasonable questions. Who receives the information? For what purposes? Can recipients pass it on? What does Nigeria obtain from products developed using its specimens? Who can refuse a transfer, and what happens to essential services if funding is withdrawn?

These questions do not presume wrongdoing. They are the questions competent governance should anticipate.

A government also weakens its own negotiating achievements when it fails to explain them.

If Nigeria secured stronger safeguards than those offered elsewhere, the public should be able to see that in the documents.

If weaknesses remain, disclosure allows institutions to address them before they become costly. Secrecy deprives citizens of both possibilities.

A better way to govern the agreement

Nigeria should first publish a complete, authenticated package on a single official portal: the signed MoU, associated agreements, operative annexes, subsequent amendments and the status of any instruments still under negotiation.

Each document should have a date and version history.

A plain-language explanation should distinguish US funding from Nigerian expenditure and set out the conditions attached to each.

Publication should protect personal records and genuinely sensitive security details. Any redaction should be narrow, explained and open to independent review.

Protecting patient information is entirely compatible with publishing the rules governing its use.

Second, government should publish an assessment of the bargain. This should explain the alternatives considered, expected benefits, financial exposure and safeguards.

It need not reveal every confidential exchange with Washington.

It should show why officials judged the final terms acceptable, where risks remain and which institutions bear responsibility for managing them.

Third, the relevant regulators should answer in their own institutional voices.

NAFDAC should clarify its continuing powers over inspection, approval and enforcement.

The Nigeria Data Protection Commission should explain the lawful basis, privacy safeguards and oversight for any cross-border health-data access.

The Nigeria Centre for Disease Control and Prevention should set out the public-health justification and approval procedures for specimen transfers.

A ministerial assurance should be supported by the institutions expected to implement it.

Their explanation must distinguish anonymised statistics from identifiable patient records, and distinguish pathogen sequence information from other sensitive data.

Describing all these as simply ‘health data’ obscures the different risks and protections they require.

Fourth, legislative oversight should examine the whole arrangement, rather than only its headline funding.

Relevant National Assembly committees should hold a public hearing involving regulators, health professionals, patient representatives and independent experts.

They should examine each instrument’s legal status separately. Calling the main MoU non-binding does not adequately explain every associated agreement or the practical consequences of funding conditions.

Fifth, Nigeria should establish measurable safeguards for implementation.

Public reporting can show transfer volumes, categories of recipients, approvals and benefits received without exposing individual patients or sensitive specimens. Independent audits should verify compliance.

Where review reveals gaps, government should seek stronger controls on secondary use and clearer commitments on affordable access to resulting diagnostics and treatments.

Finally, the financing transition needs a credible continuity plan. Increased domestic spending can strengthen health sovereignty.

But citizens need to know which budgets will finance it, how expenditure will be verified and how essential care will be sustained during a dispute or funding interruption.

A transition that exists principally in announcements offers little protection to a patient needing uninterrupted treatment.

These measures should become standard practice for major international agreements affecting public resources and rights.

Government should designate an accountable disclosure officer, publish material terms promptly after signature and provide scheduled implementation reports.

Public access should not depend on a controversy becoming embarrassing enough to compel a response.

The debate must remain open

Ghana’s decision does not oblige Nigeria to reach the same conclusion. Different financing needs, institutional capacities and negotiated safeguards can justify different choices.

Nigeria’s government must nevertheless demonstrate the quality of its own decision through evidence that the public can examine.

Health sovereignty includes the capacity to cooperate internationally on terms that protect citizens. Its democratic foundation is weakened when those citizens cannot understand the commitments made in their name.

Mahama’s interview has made renewed scrutiny inevitable. The answer is to reopen the debate with the complete documents, institutional explanations and an opportunity for independent challenge.

Where concerns are unfounded, evidence can resolve them. Where weaknesses are real, government should correct them.

Nigeria cannot credibly ask the public to accept the benefits of the agreement while leaving its consequential conditions inadequately explained.

It cannot and should not hide behind secrecy or silence. Good governance requires a decision that can withstand scrutiny, and information good enough to make that scrutiny possible.

By Collins Nweke